Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

21.82 +0.52 (+2.46%)

Streaming Delayed Price Updated: 10:09 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗

December 11, 2025

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Via Benzinga

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

December 11, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗

November 27, 2025

Roivant (ROIV) Q2 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Preview For Roivant Sciences ↗

November 07, 2025

Via Benzinga

A Glimpse of Roivant Sciences's Earnings Potential ↗

August 08, 2025

Via Benzinga

Looking Into Roivant Sciences Ltd's Recent Short Interest ↗

November 11, 2025

Via Benzinga

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

November 10, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 27, 2025

From Roivant Sciences

Via GlobeNewswire

6 Analysts Assess Roivant Sciences: What You Need To Know ↗

September 18, 2025

Via Benzinga

What Does the Market Think About Roivant Sciences? ↗

July 23, 2025

Via Benzinga

Peering Into Roivant Sciences's Recent Short Interest ↗

June 25, 2025

Via Benzinga

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗

September 17, 2025

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,...

Via Stocktwits

Why Roivant Sciences Stock Is Soaring Today ↗

September 17, 2025

The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.

Via The Motley Fool

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗

September 17, 2025

Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗

September 17, 2025

The company is working on a treatment for an autoimmune disease that affects the skin and muscles.

Via Investor's Business Daily

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

September 17, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

September 11, 2025

From Roivant Sciences

Via GlobeNewswire

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

September 04, 2025

From Pulmovant, Inc.

Via GlobeNewswire

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

September 03, 2025

From Roivant Sciences

Via GlobeNewswire

Why Roivant Sciences Stock Bounced Back on Tuesday ↗

August 12, 2025

Investors were in a forgiving mood after Monday's dispiriting earnings release.

Via The Motley Fool

Why Roivant Sciences Stock Was Slipping on Monday ↗

August 11, 2025

The distinctive biotech wasn't a sector favorite as the trading week began.

Via The Motley Fool

Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports

August 11, 2025

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings....

Via MarketMinute

Topics Economy Stocks

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

August 11, 2025

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

July 28, 2025

From Roivant Sciences

Via GlobeNewswire

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025

From Pulmovant, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.